Document is current
Any future updates will be listed below
-
Authors
Akkari, Leila https://orcid.org/0000-0001-5479-641X
Amit, Ido https://orcid.org/0000-0003-2968-877X
Bronte, Vincenzo https://orcid.org/0000-0002-3741-5141
Fridlender, Zvi G. https://orcid.org/0000-0002-6122-1988
Gabrilovich, Dmitry I. https://orcid.org/0000-0001-9913-6407
Ginhoux, Florent https://orcid.org/0000-0002-2857-7755
Hedrick, Catherine C.
Ostrand-Rosenberg, Suzanne https://orcid.org/0000-0002-2095-9732
- License Information
-
More Information
Article History
Accepted: 18 June 2024
First Online: 5 July 2024
Competing interests
: I.A. is an advisor to Immunai. D.I.G. is an employee and shareholder of AstraZeneca. Z.G.F. is a co-founder and CMO of ImmunyX, focused on neutrophil modulation in disease; and on the scientific advisory board of TigaTx, which is developing an IgA therapeutic monoclonal antibody platform for solid tumours. The other authors declare no competing interests.
